stockrow
Friday 6 November 2026
Export SYRE’s income statement to Excel — free account
Spyre Therapeutics, Inc.
SYRE Healthcare Biotechnology
Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.
- EPS
- −624.8%
- Free cash flow
- −108.8%
Quarter to September 2026, against a year earlier
102.07
5.48
+5.67%
Follow SYRE
Alert me
Spyre Therapeutics, Inc. (SYRE) Total debt
Spyre Therapeutics, Inc.'s total debt at the end of fiscal 2022 was $4.6M, down 15.2% from $5.5M in fiscal 2021. At the end of the quarter to 30 September 2023 it was $387.1M. Spyre Therapeutics, Inc. ranks 36th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $4.6M | (15.21%) |
| FY2021 | $5.5M | (0.76%) |
| FY2020 | $5.5M | 7.77% |
| FY2019 | $5.1M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $387.1M | 91.96% |
| Jun 2023 | $201.7M | 4,450.98% |
| Mar 2023 | $4.4M | (4.61%) |
| Dec 2022 | $4.6M | (2.13%) |
| 15 more quarters | Free account |
Total debt against peers
| Company | Total debt |
|---|---|
| IBRX ImmunityBio, Inc. compare | $774.4M |
| TGTX TG Therapeutics, Inc. compare | $745.4M |
| CAI Caris Life Sciences,�Inc. compare | $393.3M |
| SYRE Spyre Therapeutics, Inc. | $387.1M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | $341.3M |
| CYTK Cytokinetics, Incorporated compare | $174.4M |
| TWST Twist Bioscience Corporation compare | $15.0M |
| KRYS Krystal Biotech, Inc. compare | $8.3M |
| PTGX Protagonist Therapeutics, Inc. compare | $1.8M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on SYRE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement